Business Description
Nektar Therapeutics
NAICS : 325412
SIC : 2834
ISIN : US6402681083
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.42 | |||||
Equity-to-Asset | 0.23 | |||||
Debt-to-Equity | 1.41 | |||||
Debt-to-EBITDA | -0.77 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -14.38 | |||||
Beneish M-Score | 5.68 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -17.9 | |||||
3-Year EBITDA Growth Rate | 16.5 | |||||
3-Year EPS without NRI Growth Rate | 30.5 | |||||
3-Year FCF Growth Rate | 17.2 | |||||
3-Year Book Growth Rate | -51.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 9.08 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -7.07 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 24.18 | |||||
9-Day RSI | 36.18 | |||||
14-Day RSI | 42.93 | |||||
6-1 Month Momentum % | -13.82 | |||||
12-1 Month Momentum % | 188.36 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.15 | |||||
Quick Ratio | 4.9 | |||||
Cash Ratio | 4.73 | |||||
Days Inventory | 158.77 | |||||
Days Sales Outstanding | 7.49 | |||||
Days Payable | 59.55 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2 | |||||
Shareholder Yield % | -5.88 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 59.22 | |||||
Operating Margin % | -145.03 | |||||
Net Margin % | -190.09 | |||||
FCF Margin % | -188.25 | |||||
ROE % | -127.63 | |||||
ROA % | -42.69 | |||||
ROIC % | -157.07 | |||||
3-Year ROIIC % | -72.75 | |||||
ROC (Joel Greenblatt) % | -409.14 | |||||
ROCE % | -42.11 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 2.63 | |||||
PB Ratio | 2.89 | |||||
Price-to-Tangible-Book | 2.91 | |||||
EV-to-EBIT | -0.47 | |||||
EV-to-EBITDA | -0.49 | |||||
EV-to-Revenue | 0.76 | |||||
EV-to-Forward-Revenue | 0.87 | |||||
EV-to-FCF | -0.4 | |||||
Price-to-Median-PS-Value | 0.26 | |||||
Price-to-Net-Current-Asset-Value | 7.35 | |||||
Price-to-Net-Cash | 31.25 | |||||
Earnings Yield (Greenblatt) % | -212.77 | |||||
FCF Yield % | -76.22 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Nektar Therapeutics Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 93.157 | ||
EPS (TTM) ($) | -0.9 | ||
Beta | 2.62 | ||
Volatility % | 86.5 | ||
14-Day RSI | 42.93 | ||
14-Day ATR ($) | 0.070949 | ||
20-Day SMA ($) | 1.337035 | ||
12-1 Month Momentum % | 188.36 | ||
52-Week Range ($) | 0.435 - 1.925 | ||
Shares Outstanding (Mil) | 184.08 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Nektar Therapeutics Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Nektar Therapeutics Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Nektar Therapeutics Frequently Asked Questions
What is Nektar Therapeutics(LTS:0UNL)'s stock price today?
When is next earnings date of Nektar Therapeutics(LTS:0UNL)?
Does Nektar Therapeutics(LTS:0UNL) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |